AbCellera Biologics (ABCL) is trading up at $13.78 (+0.29%), as of the latest quote. It operates in the Health Care sector.
| FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $11.6M | $233.2M | $375.2M | $485.4M | $38.0M | $28.8M | $75.1M |
| Growth (year over year) | — | +1907.9% | +60.9% | +29.4% | −92.2% | −24.2% | +160.6% |
| Operating income | −$4.12M | $156.0M | $204.4M | $216.5M | −$237.2M | −$314.8M | −$217.1M |
| Operating margin | −35.5% | 66.9% | 54.5% | 44.6% | −623.8% | −1091.7% | −289.0% |
| Net income | −$2.21M | $118.9M | $153.5M | $158.5M | −$146.4M | −$162.9M | −$146.4M |
| Net margin | −19.0% | 51.0% | 40.9% | 32.7% | −385.0% | −564.8% | −194.9% |
| EPS (diluted) | −$0.01 | $0.45 | $0.48 | $0.50 | −$0.51 | −$0.55 | −$0.49 |
| Balance sheet | |||||||
| Cash and equivalents | — | $594.1M | $476.1M | $386.5M | $133.3M | $156.3M | $128.5M |
| Total assets | — | $1.01B | $1.32B | $1.54B | $1.49B | $1.36B | $1.36B |
| Total liabilities | — | $175.0M | $292.8M | $307.6M | $335.8M | $304.5M | $390.0M |
| Shareholders' equity | $10.3M | $830.5M | $1.03B | $1.23B | $1.15B | $1.06B | $966.9M |
| Cash flow | |||||||
| Operating cash flow | $2.69M | $22.7M | $244.6M | $277.4M | −$43.9M | −$108.6M | −$131.3M |
| Capital expenditure | $4.00M | $9.67M | $58.5M | $70.7M | $76.9M | $78.4M | $42.8M |
| Free cash flow | −$1.30M | $13.0M | $186.1M | $206.7M | −$120.8M | −$187.0M | −$174.1M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $6.51M | $5.05M | $4.24M | $17.1M | $8.96M | — | $8.31M | $4.05M |
| Growth (year over year) | −1.4% | −45.0% | −57.5% | +133.3% | +37.6% | — | +96.3% | −76.3% |
| Operating income | −$93.7M | −$72.8M | −$62.7M | −$49.6M | −$76.3M | — | −$57.5M | −$62.8M |
| Operating margin | −1439.4% | −1441.0% | −1479.6% | −290.2% | −851.8% | — | −691.7% | −1550.0% |
| Net income | −$51.1M | −$34.2M | −$45.6M | −$34.7M | −$57.1M | — | −$43.2M | −$55.4M |
| Net margin | −785.4% | −677.6% | −1077.2% | −203.3% | −637.8% | — | −519.1% | −1368.6% |
| EPS (diluted) | −$0.17 | −$0.11 | −$0.15 | −$0.12 | −$0.19 | — | −$0.14 | −$0.18 |
| Balance sheet | ||||||||
| Cash and equivalents | $126.6M | $156.3M | $159.3M | $92.4M | $83.2M | $128.5M | $77.1M | $120.1M |
| Total assets | $1.39B | $1.36B | $1.34B | $1.40B | $1.36B | $1.36B | $1.31B | $1.31B |
| Total liabilities | $314.7M | $304.5M | $321.2M | $395.0M | $392.0M | $390.0M | $369.0M | $411.6M |
| Shareholders' equity | $1.08B | $1.06B | $1.02B | $1.01B | $964.0M | $966.9M | $938.1M | $896.0M |
| Cash flow | ||||||||
| Operating cash flow | −$28.9M | −$8.00M | −$11.6M | −$32.4M | −$52.6M | — | −$33.5M | $25.9M |
| Capital expenditure | $18.5M | $15.6M | $10.6M | $13.4M | $8.93M | — | $3.83M | $2.13M |
| Free cash flow | −$47.4M | −$23.6M | −$22.2M | −$45.8M | −$61.5M | — | −$37.4M | $23.8M |
From AbCellera Biologics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
No recent news mentioning AbCellera Biologics in our feed yet.